TY - JOUR
T1 - Treatment of opioid-dependent adolescents and young adults with buprenorphine
AU - Subramaniam, Geetha A.
AU - Fishman, Marc J.
AU - Woody, George
PY - 2009
Y1 - 2009
N2 - Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.
AB - Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.
UR - http://www.scopus.com/inward/record.url?scp=70349745513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349745513&partnerID=8YFLogxK
U2 - 10.1007/s11920-009-0054-5
DO - 10.1007/s11920-009-0054-5
M3 - Review article
C2 - 19785976
AN - SCOPUS:70349745513
SN - 1523-3812
VL - 11
SP - 360
EP - 363
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
IS - 5
ER -